Analysts Expect BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to Post -$1.27 EPS

Wall Street brokerages forecast that BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) will report earnings per share of ($1.27) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. The highest EPS estimate is ($0.95) and the lowest is ($1.73). BioXcel Therapeutics posted earnings per share of ($1.11) in the same quarter last year, which would indicate a negative year over year growth rate of 14.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioXcel Therapeutics will report full-year earnings of ($4.63) per share for the current financial year, with EPS estimates ranging from ($6.07) to ($2.61). For the next financial year, analysts forecast that the business will post earnings of ($3.95) per share, with EPS estimates ranging from ($8.05) to ($0.33). Zacks’ EPS calculations are an average based on a survey of research firms that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last released its earnings results on Monday, May 9th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.09. During the same period in the prior year, the business posted ($1.08) EPS.

Several analysts have issued reports on BTAI shares. Canaccord Genuity Group dropped their price objective on BioXcel Therapeutics from $84.00 to $75.00 in a research note on Friday. UBS Group dropped their price objective on BioXcel Therapeutics from $88.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th. Truist Financial dropped their price objective on BioXcel Therapeutics from $125.00 to $71.00 in a research note on Tuesday. HC Wainwright upped their price objective on BioXcel Therapeutics from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, April 14th. Finally, Bank of America upped their price objective on BioXcel Therapeutics from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, April 6th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $68.43.

NASDAQ:BTAI opened at $11.74 on Friday. The stock’s 50 day moving average price is $16.26 and its two-hundred day moving average price is $19.85. The firm has a market capitalization of $328.60 million, a price-to-earnings ratio of -2.85 and a beta of 1.31. BioXcel Therapeutics has a 12-month low of $9.08 and a 12-month high of $39.00.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its stake in shares of BioXcel Therapeutics by 122.2% during the third quarter. Rockefeller Capital Management L.P. now owns 2,000 shares of the company’s stock worth $60,000 after purchasing an additional 1,100 shares during the period. Macquarie Group Ltd. increased its stake in shares of BioXcel Therapeutics by 136.1% during the third quarter. Macquarie Group Ltd. now owns 3,197 shares of the company’s stock worth $97,000 after purchasing an additional 1,843 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of BioXcel Therapeutics during the third quarter worth approximately $109,000. Ensign Peak Advisors Inc acquired a new stake in BioXcel Therapeutics during the fourth quarter worth approximately $110,000. Finally, Metropolitan Life Insurance Co NY grew its position in BioXcel Therapeutics by 22.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,882 shares of the company’s stock worth $148,000 after buying an additional 909 shares in the last quarter. Institutional investors own 49.77% of the company’s stock.

About BioXcel Therapeutics (Get Rating)

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.

See Also